ABBVIE

UCB and Biogen's lupus drug, dapirolizumab pegol, met primary endpoint in Phase III PHOENYCS GO trial, showing improvement in moderate-to-severe SLE. The drug also demonstrated clinical improvements in secondary endpoints and a consistent safety profile. UCB's stock rose 2.57% post-announcement. Detailed data will be presented at an upcoming medical conference.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

EMA's CHMP recommends marketing authorization for mirvetuximab soravtansine (Elahere) for FRa-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer patients who have received 1-3 prior treatments. Supported by MIRASOL trial results, the European Commission decision is expected later this year.

EMA's CHMP recommends AbbVie's mirvetuximab soravtansine for FRα-positive, platinum-resistant ovarian cancer. Based on Phase III MIRASOL trial, it targets patients with high FRα levels, previously treated with 1-3 regimens. The European Commission will decide later this year, following FDA's full approval in the US as ELAHERE in March.

Bristol Myers Squibb awaits FDA decision on KarXT, a novel schizophrenia treatment potentially representing the first new approach in decades. KarXT, acquired via $14 billion deal with Karuna Therapeutics, targets M1 and M4 muscarinic receptors, offering efficacy without antipsychotic side effects. Other companies, including Neurocrine Biosciences, AbbVie, Reviva Pharmaceuticals, Boehringer Ingelheim, and Alto Neuroscience, are also developing schizophrenia treatments, focusing on various mechanisms to address positive, negative, and cognitive symptoms.

Summit Therapeutics, a 21-year-old biotech with 130 employees and no revenue, saw its market cap surge due to positive data on its cancer drug candidate, ivonescimab, outperforming Merck's Keytruda. Co-CEO Maky Zanganeh's shares rose 17-fold, making her a billionaire. The drug, licensed from Akeso, requires a global Phase 3 trial for FDA approval. Zanganeh, born in Iran, followed an unconventional path to biotech leadership, collaborating with co-CEO Robert Duggan, who turned around Pharmacyclics.

New migraine drugs like rimegepant and ubrogepant are no more effective than traditional painkillers and even less so than triptans, according to a global analysis. Triptans are recommended as the first line of treatment, with traditional painkillers as a second option for those unable to take triptans due to heart problems.

The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.